<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39201383</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>16</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8698</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25168698</ELocationID><Abstract><AbstractText>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated hemolysis and potentially life-threatening complications. Pegcetacoplan, an inhibitor of complement components C3 and C3b, was approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2021. A recent expansion to its indication by the EMA has made pegcetacoplan available for the treatment of both complement inhibitor-naïve and -experienced patients with PNH who have hemolytic anemia, a similarly broad patient population as in the US. This approval was based on results from the Phase 3 PEGASUS study, where pegcetacoplan showed superiority over the C5 inhibitor eculizumab with regard to improving the hemoglobin level in patients with anemia despite eculizumab treatment, and the Phase 3 PRINCE study, where pegcetacoplan showed superiority over supportive care with regard to hemoglobin stabilization and improving the lactate dehydrogenase level in complement inhibitor-naïve patients. In light of this recent indication expansion by the EMA, this article describes how the strong efficacy of pegcetacoplan is linked to its mechanism of action, which provides broad hemolysis control over both intravascular and extravascular hemolysis to improve a range of disease markers and enhance patients' quality of life. Furthermore, additional data and learnings obtained from over 3 years of experience with pegcetacoplan are summarized, including long-term efficacy and safety results, real-world clinical experiences, pharmacokinetic characteristics, and extensive practical guidance for the first-to-market proximal complement inhibitor for PNH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Horneff</LastName><ForeName>Regina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Swedish Orphan Biovitrum AB, 171 65 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czech</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Swedish Orphan Biovitrum AB, 171 65 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Apellis Pharmaceuticals, Inc., Waltham, MA 02451, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Swedish Orphan Biovitrum AB, 171 65 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>A3ULP0F556</RegistryNumber><NameOfSubstance UI="C481642">eculizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051056">Complement Inactivating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-43-8</RegistryNumber><NameOfSubstance UI="D003179">Complement C3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006457" MajorTopicYN="Y">Hemoglobinuria, Paroxysmal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="Y">Complement C3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051056" MajorTopicYN="N">Complement Inactivating Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003179" MajorTopicYN="N">Complement C3b</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="N">United States Food and Drug Administration</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C3</Keyword><Keyword MajorTopicYN="N">PNH</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">paroxysmal nocturnal hemoglobinuria</Keyword><Keyword MajorTopicYN="N">pegcetacoplan</Keyword><Keyword MajorTopicYN="N">proximal inhibitor</Keyword></KeywordList><CoiStatement>R. Horneff, B. Czech and E. Surova report employment by and shares in Swedish Orphan Biovitrum AB. M. Yeh reports employment by and shares in Apellis Pharmaceuticals, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39201383</ArticleId><ArticleId IdType="pmc">PMC11354333</ArticleId><ArticleId IdType="doi">10.3390/ijms25168698</ArticleId><ArticleId IdType="pii">ijms25168698</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hill A., DeZern A.E., Kinoshita T., Brodsky R.A. Paroxysmal nocturnal haemoglobinuria. Nat. Rev. Dis. Primers. 2017;3:17028. doi: 10.1038/nrdp.2017.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.28</ArticleId><ArticleId IdType="pmc">PMC7879566</ArticleId><ArticleId IdType="pubmed">28516949</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier H., Röth A., Araten D.J., Kanakura Y., Larratt L., Shammo J.M., Wilson A., Shayan G., Maciejewski J.P. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): Updated analysis from the International PNH Registry. Ann. Hematol. 2020;99:1505–1514. doi: 10.1007/s00277-020-04052-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-020-04052-z</ArticleId><ArticleId IdType="pmc">PMC7316848</ArticleId><ArticleId IdType="pubmed">32390114</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano A.M., Marotta S., Ricci P., Marano L., Frieri C., Cacace F., Sica M., Kulasekararaj A., Calado R.T., Scheinberg P., et al. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Front. Immunol. 2019;10:1157. doi: 10.3389/fimmu.2019.01157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01157</ArticleId><ArticleId IdType="pmc">PMC6587878</ArticleId><ArticleId IdType="pubmed">31258525</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle N.S., Church S.E., Fremeaux-Bacchi V., Roumenina L.T. Complement System Part I—Molecular Mechanisms of Activation and Regulation. Front. Immunol. 2015;6:262. doi: 10.3389/fimmu.2015.00262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00262</ArticleId><ArticleId IdType="pmc">PMC4451739</ArticleId><ArticleId IdType="pubmed">26082779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly R.J., Holt M., Vidler J., Arnold L.M., Large J., Forrest B., Barnfield C., Pike A., Griffin M., Munir T., et al. Treatment Outcomes of Complement Protein C5 Inhibition in 509 UK Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood. 2024;143:1157–1166. doi: 10.1182/blood.2023021762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2023021762</ArticleId><ArticleId IdType="pubmed">38142401</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers G., Weitz I., Lamy T., Cahn J.-Y., Kroon H.-A., Severino B., Uranga M.T., Alonso M.S., Vela J.A.G., Hill A. Disease-Related Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood. 2007;110:3683. doi: 10.1182/blood.V110.11.3683.3683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V110.11.3683.3683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura J.-I., Kanakura Y., Ware R.E., Shichishima T., Nakakuma H., Ninomiya H., de Castro C.M., Hall S., Kanamaru A., Sullivan K.M., et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004;83:193–207. doi: 10.1097/01.md.0000126763.68170.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000126763.68170.46</ArticleId><ArticleId IdType="pubmed">15118546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillmen P., Lewis S.M., Bessler M., Luzzatto L., Dacie J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 1995;333:1253–1258. doi: 10.1056/NEJM199511093331904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199511093331904</ArticleId><ArticleId IdType="pubmed">7566002</ArticleId></ArticleIdList></Reference><Reference><Citation>Devalet B., Mullier F., Chatelain B., Dogné J.-M., Chatelain C. The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: A review. J. Extracell. Vesicles. 2014;3:23304. doi: 10.3402/jev.v3.23304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v3.23304</ArticleId><ArticleId IdType="pmc">PMC3965713</ArticleId><ArticleId IdType="pubmed">24672668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985–4996. doi: 10.1182/blood-2012-09-311381. quiz 5105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-09-311381</ArticleId><ArticleId IdType="pubmed">23610373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill A., Rother R.P., Wang X., Morris Jr S.M., Quinn-Senger K., Kelly R., Richards S.J., Bessler M., Bell L., Hillmen P., et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 2010;149:414–425. doi: 10.1111/j.1365-2141.2010.08096.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08096.x</ArticleId><ArticleId IdType="pubmed">20230403</ArticleId></ArticleIdList></Reference><Reference><Citation>Socié G., Schrezenmeier H., Muus P., Lisukov I., Röth A., Kulasekararaj A., Lee J.W., Araten D., Hill A., Brodsky R., et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: An analysis of the International PNH Registry. Intern. Med. J. 2016;46:1044–1053. doi: 10.1111/imj.13160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.13160</ArticleId><ArticleId IdType="pubmed">27305361</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillmen P., Elebute M., Kelly R., Urbano-Ispizua A., Hill A., Rother R.P., Khursigara G., Fu C.-L., Omine M., Browne P., et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 2010;85:553–559. doi: 10.1002/ajh.21757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21757</ArticleId><ArticleId IdType="pubmed">20658586</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle N.S., Noe R., Halbwachs-Mecarelli L., Fremeaux-Bacchi V., Roumenina L.T. Complement System Part II: Role in Immunity. Front. Immunol. 2015;6:257. doi: 10.3389/fimmu.2015.00257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00257</ArticleId><ArticleId IdType="pmc">PMC4443744</ArticleId><ArticleId IdType="pubmed">26074922</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodsky R.A. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804–2811. doi: 10.1182/blood-2014-02-522128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-02-522128</ArticleId><ArticleId IdType="pmc">PMC4215311</ArticleId><ArticleId IdType="pubmed">25237200</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammo J., Gajra A., Patel Y., Tomazos I., Kish J., Hill A., Sierra J.R., Araten D. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study. J. Blood Med. 2022;13:425–437. doi: 10.2147/JBM.S361863.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JBM.S361863</ArticleId><ArticleId IdType="pmc">PMC9380823</ArticleId><ArticleId IdType="pubmed">35983240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill A., Rother R.P., Arnold L., Kelly R., Cullen M.J., Richards S.J., Hillmen P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95:567–573. doi: 10.3324/haematol.2009.007229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2009.007229</ArticleId><ArticleId IdType="pmc">PMC2857185</ArticleId><ArticleId IdType="pubmed">20145265</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano A.M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., Ricci P., Alfinito F., Camera A., Gianfaldoni G., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094–4100. doi: 10.1182/blood-2008-11-189944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-11-189944</ArticleId><ArticleId IdType="pubmed">19179465</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano A.M., Peffault de Latour R. How we(’ll) treat paroxysmal nocturnal haemoglobinuria: Diving into the future. Br. J. Haematol. 2022;196:288–303. doi: 10.1111/bjh.17753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17753</ArticleId><ArticleId IdType="pmc">PMC9291300</ArticleId><ArticleId IdType="pubmed">34355382</ArticleId></ArticleIdList></Reference><Reference><Citation>Panse J., Sicre de Fontbrune F., Burmester P., Piggin M., Matos J.E., Costantino H., Wilson K., Hakimi Z., Nazir J., Desgraz R., et al. The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life. Eur. J. Haematol. 2022;109:351–363. doi: 10.1111/ejh.13816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13816</ArticleId><ArticleId IdType="pmc">PMC9545353</ArticleId><ArticleId IdType="pubmed">35746830</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingli D., Matos J.E., Lehrhaupt K., Krishnan S., Yeh M., Fishman J., Sarda S.P., Baver S.B. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: Results from a US patient survey. Ann. Hematol. 2022;101:251–263. doi: 10.1007/s00277-021-04715-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-021-04715-5</ArticleId><ArticleId IdType="pmc">PMC8720163</ArticleId><ArticleId IdType="pubmed">34973099</ArticleId></ArticleIdList></Reference><Reference><Citation>EMPAVELI (Pegcetacoplan) US Prescribing Information.  [(accessed on 6 August 2024)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215014s006lbl.pdf.</Citation></Reference><Reference><Citation>Aspaveli (Pegcetacoplan) EMA Summary of Product Characteristics.  [(accessed on 6 August 2024)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/aspaveli-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>de Castro C., Grossi F., Weitz I.C., Maciejewski J., Sharma V., Roman E., Brodsky R.A., Tan L., Di Casoli C., El Mehdi D., et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am. J. Hematol. 2020;95:1334–1343. doi: 10.1002/ajh.25960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25960</ArticleId><ArticleId IdType="pmc">PMC7693064</ArticleId><ArticleId IdType="pubmed">33464651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.S.M., Pullon H.W.H., Amine I., Bogdanovic A., Deschatelets P., Francois C.G., Ignatova K., Issaragrisil S., Niparuck P., Numbenjapon T., et al. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann. Hematol. 2022;101:1971–1986. doi: 10.1007/s00277-022-04903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-022-04903-x</ArticleId><ArticleId IdType="pmc">PMC9375762</ArticleId><ArticleId IdType="pubmed">35869170</ArticleId></ArticleIdList></Reference><Reference><Citation>Peffault de Latour R., Szer J., Weitz I.C., Röth A., Höchsmann B., Panse J., Usuki K., Griffin M., Kiladjian J.-J., de Castro C.M., et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9:e648–e659. doi: 10.1016/S2352-3026(22)00210-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00210-1</ArticleId><ArticleId IdType="pubmed">36055332</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano A.M., Peffault De Latour R., Marano L., Frieri C. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. Semin. Immunol. 2022;59:101618. doi: 10.1016/j.smim.2022.101618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2022.101618</ArticleId><ArticleId IdType="pubmed">35764467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillmen P., Szer J., Weitz I., Röth A., Höchsmann B., Panse J., Usuki K., Griffin M., Kiladjian J.-J., de Castro C.M., et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N. Engl. J. Med. 2021;384:1028–1037. doi: 10.1056/NEJMoa2029073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2029073</ArticleId><ArticleId IdType="pubmed">33730455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulasekararaj A.G., Kuter D.J., Griffin M., Weitz I.C., Röth A. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Rev. 2023;59:101041. doi: 10.1016/j.blre.2023.101041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2023.101041</ArticleId><ArticleId IdType="pubmed">36732204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.S.M., Navarro-Cabrera J.R., Comia N.S., Goh Y.T., Idrobo H., Kongkabpan D., Gómez-Almaguer D., Al-Adhami M., Ajayi T., Alvarenga P., et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7:2468–2478. doi: 10.1182/bloodadvances.2022009129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022009129</ArticleId><ArticleId IdType="pmc">PMC10241857</ArticleId><ArticleId IdType="pubmed">36848639</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castro C.M., Mulherin B., Patriquin C.J., Selvaratnam V., Wong R.S.M., Kelly R.J., Tan L., Hillmen P., Zhang D., Savage J., et al. Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years. Blood. 2023;142((Suppl. S1)):574. doi: 10.1182/blood-2023-181054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-181054</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Araten D.J., Yeh M., Al-Adhami M., Horneff R., Grossi F. Pegcetacoplan Corrects Hyperbilirubinemia in Both Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and in Patients with PNH Who Previously Received Eculizumab. Blood. 2022;140((Suppl. S1)):11447–11448. doi: 10.1182/blood-2022-166623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-166623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R.S.M. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Ther. Adv. Hematol. 2022;13:20406207221114673. doi: 10.1177/20406207221114673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406207221114673</ArticleId><ArticleId IdType="pmc">PMC9340389</ArticleId><ArticleId IdType="pubmed">35923770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillmen P., Risitano A.M., Peffault de Latour R. Pegcetacoplan versus Eculizumab in PNH. Reply. N. Engl. J. Med. 2021;385:1723–1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34706185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D., Johansson P., Ueda Y., Tomazos I., Gustovic P., Wang A., Patel A.S., Schrezenmeier H. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: A derivation from international PNH registry patient data. J. Patient Rep. Outcomes. 2023;7:63. doi: 10.1186/s41687-023-00609-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-023-00609-4</ArticleId><ArticleId IdType="pmc">PMC10322798</ArticleId><ArticleId IdType="pubmed">37405515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D., Lai J.-S., Chang C.-H., Peterman A., Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94:528–538. doi: 10.1002/cncr.10245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.10245</ArticleId><ArticleId IdType="pubmed">11900238</ArticleId></ArticleIdList></Reference><Reference><Citation>Peffault de Latour R., de Castro C., Mulherin B., Patriquin C.J., Selvaratnam V., Kelly R.J., Griffin M., Surova E., Szamosi J., Uchendu U., et al. P819: Characterization of clinically significant breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan; Proceedings of the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Kelly R.J., Nishimori H., Horneff R., Hillmen P., Al-Adhami M., Lallier S., Gerber G.F. Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings. Res. Pract. Thromb. Haemost. 2024;8:102416. doi: 10.1016/j.rpth.2024.102416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2024.102416</ArticleId><ArticleId IdType="pmc">PMC11135031</ArticleId><ArticleId IdType="pubmed">38812989</ArticleId></ArticleIdList></Reference><Reference><Citation>Panse J., de Latour R.P., Szamosi J., Horneff R., Hillmen P., Wong R.S.M. P816: Long-term outcomes of pegcetacoplan treatment in patients with paroxysmal nocturnal hemoglobinuria and baseline hemoglobin levels greater than 10 grams per deciliter; Proceedings of the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Usuki K., Tamura S., Uchida T., Röth A., de Castro C.M., Weitz I., Yeh M., Szamosi J., Persson E., Peffault de Latour R. OS2-5C-2: Evaluation of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Patients with Aplastic Anemia; Presented at the Japanese Society of Hematology Congress; Fukuoka, Japan. 14–16 October 2022; Oct 14–16,</Citation></Reference><Reference><Citation>Bogdanovic A., Tse E., Szamosi J., Wong R. P794: Evaluation of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Patients with Aplastic Anemia in the Prince Study. Hemasphere. 2023;7:e71651d4. doi: 10.1097/01.HS9.0000970080.71651.d4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.HS9.0000970080.71651.d4</ArticleId></ArticleIdList></Reference><Reference><Citation>Szer J., Panse J., Kulasekararaj A., Oliver M., Fattizzo B., Nishimura J.-I., Horneff R., Szamosi J., Peffault de Latour R. Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function. Int. J. Mol. Sci. 2024;25:8591. doi: 10.3390/ijms25168591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25168591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman J., Min J., Arnett L., Shenoy A. Improvements in Hemoglobin and Cognitive Function from Opera: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood. 2023;142((Suppl. S1)):5637. doi: 10.1182/blood-2023-189167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2023-189167</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman J., Min J., Arnett L., Shenoy A. P757: Incidence Rates of Healthcare Resource Utilization and Hemoglobin Levels During Opera: A Real-World Study of Pegcetacoplan Treatment in Us Adults with Paroxysmal Nocturnal Hemoglobinuria. Hemasphere. 2023;7:e4809314. doi: 10.1097/01.HS9.0000969932.48093.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.HS9.0000969932.48093.14</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman J., Min J., Arnett L., Shenoy A. D4: Healthcare resource utilization from OPERA: A real-world study of pegcetacoplan treatment in US adults with paroxysmal nocturnal hemoglobinuria (PNH); Presented at the Academy of Managed Care Pharmacy Nexus Congress; Orlando, FL, USA. 16–19 October 2023; Oct 16–19,</Citation></Reference><Reference><Citation>Fishman J., Min J., Arnett L., Shenoy A. CO33 Early Hemoglobin and Quality-of-Life Trends from OPERA: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria. Value Health. 2023;26:S20. doi: 10.1016/j.jval.2023.03.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2023.03.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson K., Rich C., Hakimi Z., Horneff R., Fishman J., Mellor J., Earl L., Taylor Y., Simons A., Conyers J., et al. Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health-related quality of life and productivity. Eur. J. Haematol. 2024;112:516–529. doi: 10.1111/ejh.14139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.14139</ArticleId><ArticleId IdType="pubmed">37994576</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin M., Kelly R., Brindel I., Maafa L., Trikha R., Muus P., Munir T., Varghese A.M., Mitchell L., Nagumantry S., et al. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 2024;99:816–823. doi: 10.1002/ajh.27242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.27242</ArticleId><ArticleId IdType="pubmed">38348608</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallejo C., González C., Fernández A., Iglesia S., Lavilla E., Benet C., Bonanad S., Carnicero F., Gaya A., González F.A., et al. P1917: Real-world experience of pegcetacoplan treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH) with unsatisfactory response to previous therapeutic approaches; Presented at the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Panse J., Kelly R., Nishimori H., Horneff R., Hillmen P., Uchendu U., Lallier S., Gerber G. P838: Thrombosis and meningococcal infection rates in pegcetacoplan patients with paroxysmal nocturnal hemoglobinuria in the post-marketing setting; Presented at the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Gonzalez C.G., Segurola L.O., Elosegui I.E., Oyarzabal A.A. PB2671: Pegcetacoplan C3 inhibitor improve residual anemia in PNH patients under treatment C5 inhibitors. Experience tertiary hospital; Presented at the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Fattizzo B., Versino F., Zaninoni A., Marcello A.P.M.L., Vercellati C., Artuso S., Barcellini W. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan. Front. Immunol. 2022;13:1060923. doi: 10.3389/fimmu.2022.1060923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1060923</ArticleId><ArticleId IdType="pmc">PMC9751407</ArticleId><ArticleId IdType="pubmed">36532073</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanka P., Reagan J. PB0722: Resolution of hemolysis in a patient with PNH treated with pegcetacoplan; Presented at the International Society on Thrombosis and Haemostasis Congress; Montreal, QC, Canada. 24–28 June 2023; Jun 24–28,</Citation></Reference><Reference><Citation>Boshkos M.C., Fives K.R., Phrathep D.D., Healey K.D., Patel M. Breakthrough Hemolysis Associated with COVID-19 Vaccination and Active COVID-19 Infection in a Patient with Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report. Cureus. 2023;15:e36240. doi: 10.7759/cureus.36240.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.36240</ArticleId><ArticleId IdType="pmc">PMC10103799</ArticleId><ArticleId IdType="pubmed">37065335</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A.K., Bingham N., Szer J. Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria. EJHaem. 2023;4:710–713. doi: 10.1002/jha2.714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.714</ArticleId><ArticleId IdType="pmc">PMC10435701</ArticleId><ArticleId IdType="pubmed">37601872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pampliega M.V., Gamiz M.M., Mendez J.A., Boix S.B. PB2653: Pegcetacoplan management in patients with paroxysmal nocturnal hemoglobinuria undergoing major surgeries; Presented at the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Sánchez-Villalobos M., Belen Perez Oliva A., Campos E., José Salido Fiérrez E. PB2670: Successful treatment with anti-complement molecule pegcetacoplan in liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria; Presented at the European Hematology Association Congress; Madrid, Spain. 13–16 June 2024; Jun 13–16,</Citation></Reference><Reference><Citation>Du W., Mei L. A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria. Res. Pract. Thromb. Haemost. 2024;8:102435. doi: 10.1016/j.rpth.2024.102435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2024.102435</ArticleId><ArticleId IdType="pmc">PMC11153911</ArticleId><ArticleId IdType="pubmed">38846741</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriquin C.J., Bogdanovic A., Griffin M., Kelly R.J., Maciejewski J.P., Mulherin B., Peffault de Latour R., Röth A., Selvaratnam V., Szer J., et al. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Adv. Ther. 2024;41:2050–2069. doi: 10.1007/s12325-024-02827-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-024-02827-8</ArticleId><ArticleId IdType="pmc">PMC11052769</ArticleId><ArticleId IdType="pubmed">38573482</ArticleId></ArticleIdList></Reference><Reference><Citation>Crass R.L., Chapel S., Ajayi T. Population Pharmacokinetics of Pegcetacoplan in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria; Presented at the International PNH Interest Group Congress; Harrogate, UK. 18–19 May 2023; May 18–19,</Citation></Reference><Reference><Citation>Crass R.L., Chapel S., Ajayi T. Exposure-Response Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria; Presented at the International PNH Interest Group Congress; Harrogate, UK. 18–19 May 2023; May 18–19,</Citation></Reference><Reference><Citation>Peffault de Latour R., Griffin M., Kelly R.J., Szer J., de Castro C., Horneff R., Tan L., Yeh M., Panse J. Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024;8:2718–2725. doi: 10.1182/bloodadvances.2024012672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2024012672</ArticleId><ArticleId IdType="pmc">PMC11170155</ArticleId><ArticleId IdType="pubmed">38593241</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingli D., de Castro C., Koprivnikar J., Kulasekararaj A., Maciejewski J., Mulherin B., Panse J., Pullarkat V., Röth A., Shammo J., et al. Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria. Hematology. 2024;29:2329030. doi: 10.1080/16078454.2024.2329030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16078454.2024.2329030</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin M., Kelly R.J., Panse J.P., de Castro C., Szer J., Horneff R., Tan L., Yeh M., Peffault de Latour R. Management of Acute Breakthrough Hemolysis with Intensive Pegcetacoplan Dosing in Patients with PNH. Blood Adv. 2024;8:1776–1786. doi: 10.1182/bloodadvances.2023011691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2023011691</ArticleId><ArticleId IdType="pmc">PMC10985803</ArticleId><ArticleId IdType="pubmed">38315872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattizzo B., Cavallaro F., Oliva E.N., Barcellini W. Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective. J. Blood Med. 2022;13:327–335. doi: 10.2147/JBM.S339660.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JBM.S339660</ArticleId><ArticleId IdType="pmc">PMC9211741</ArticleId><ArticleId IdType="pubmed">35747742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulasekararaj A.G., Lazana I. Paroxysmal nocturnal hemoglobinuria: Where are we going. Am. J. Hematol. 2023;98((Suppl. S4)):S33–S43. doi: 10.1002/ajh.26882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26882</ArticleId><ArticleId IdType="pubmed">36794458</ArticleId></ArticleIdList></Reference><Reference><Citation>Peffault de Latour R., Szer J., Kulasekararaj A., Gaya A., Sica S., Nölte M., Horneff R., Lethagen S. PB2064: The COMPLETE Study: A Single Arm, Multicenter Observational Study to Evaluate Effectiveness of Pegcetacoplan under Real World Conditions in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Hemasphere. 2023;7((Suppl. S3)):e36410cc.</Citation></Reference><Reference><Citation>Oliver M., Patriquin C.J. Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations. J. Blood Med. 2023;14:613–628. doi: 10.2147/JBM.S431493.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JBM.S431493</ArticleId><ArticleId IdType="pmc">PMC10710797</ArticleId><ArticleId IdType="pubmed">38084255</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>